Engineered immune cells take on tough bone cancer in first human trial
NCT ID NCT07227571
First seen Nov 12, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This early-stage trial tests a new type of immunotherapy called CAR T-cells, which are made from a patient's own immune cells and engineered to attack cancer cells that carry a protein called FOLR1. The study enrolls up to 30 people aged 1 to 75 with advanced osteosarcoma that has come back or not responded to treatment. Participants receive the modified cells by IV along with chemotherapy to help the cells work better. The main goals are to find a safe dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OSTEOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington/Seattle Children's Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-FOLR1 CAR T-cells (a type of immune cell therapy)
What this could lead to
If it works, this could point toward a new treatment option for advanced osteosarcoma that has not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 30 participants, so it is primarily testing safety and dosing. The therapy may not shrink tumors or improve survival, and there are risks of severe side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.